News

Designed to assess the safety, tolerability and efficacy of CCX140, the randomised, double-blind, placebo-controlled study is being conducted at 90 sites throughout Europe. ChemoCentryx president and chief executive

Lundbeck agreed with each of the nine companies in 2002 to delay the launch of generic medicines of its anti-depressant. Ranbaxy Laboratories was fined more than Rs800m (€10.32m),

The Medicines and Healthcare Products Regulatory Agency (MHRA) has revealed that the company recalled two batches of the asthma drug in amber glass bottles displaying the batch numbers

Targeting peroxisome proliferator activated receptor delta (PPARd), DB959 was developed by DARA through Phase 1 trials for the treatment of diabetes and dyslipidemia. As per the company’s strategic

The US patent is titled ‘Intermediate Compounds and Processes for the Preparation of Tapentadol and Related Compounds’. Using easily available reagents, the patented and cost effective process fitting

The assumption of rights to TT-401, a dual agonist of the Glucagon-Like Peptide-1 and glucagon receptors, by Eli Lilly triggers a $7m milestone payment to Transition. As per

The company has submitted a new drug application to the Ministry of Health, Labour and Welfare in Japan for prasugrel. Data from phase 3 trial carried out in

The $1m funding will support later stage clinical trial of inhaled formulation of levodopa that is developed as an adjunct PRN therapy offering relief from intermittent debilitating motor

The acquirer, which already holds 50% stake in the company, said that the change of ownership will be completed on 1 July 2013. Founded in 2002 to manufacture